Plain-English translation of NCT07482020 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called empagliflozin can help improve how well the upper left chamber of your heart functions if you have paroxysmal atrial fibrillation (an irregular heartbeat that comes and goes), high blood pressure, and blood sugar concerns. Researchers will compare people taking this medication to people taking a placebo (a dummy pill) over 12 months, using special heart ultrasound imaging to measure changes in heart function.
People with irregular heartbeats and high blood pressure often develop weakened heart function, which can lead to serious complications like heart failure. Researchers want to see if this medication, which is already used for diabetes, might also strengthen the heart muscle in ways that prevent these complications.
You likely qualify if…
You likely don't qualify if…
You will take either the study medication or a placebo pill once daily for 12 months. You'll have heart ultrasounds performed at the beginning of the study and again after 12 months to measure how your heart function changes, along with regular visits to track your symptoms and overall heart health. Throughout the study, doctors will monitor for any signs of heart problems and record any hospitalizations or heart-related symptoms you experience.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China